FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176430891> ?p ?o ?g. }

• W3176430891 endingPage "e21088" @default.
• W3176430891 startingPage "e21088" @default.
• W3176430891 abstract "Approximately 80% of pancreatic ductal adenocarcinoma (PDAC) patients suffer from anorexia, weight loss, and asthenia. Most PDAC patients receive chemotherapy, which often worsens their nutritional status owing to the adverse effects of chemotherapy. Malnutrition of PDAC patients is known to be associated with poor prognosis; therefore, nutritional management during chemotherapy is a key factor influencing the outcome of the treatment. Mobile apps have the potential to provide readily accessible nutritional support for patients with PDAC.We aimed to evaluate the efficacy of a mobile app-based program, Noom, in patients receiving chemotherapy for PDAC.We prospectively enrolled 40 patients who were newly diagnosed with unresectable PDAC from a single university-affiliated hospital in South Korea, and randomly assigned them into a Noom user group (n=20) and a non-Noom user group (n=20). The 12-week in-app interventions included meal and physical activity logging as well as nutritional education feedback from dietitians. The non-Noom user group did not receive any nutrition intervention. The primary outcomes were the changes in the nutritional status and quality of life (QoL) from the baseline to 12 weeks. The secondary outcomes included the changes in the skeletal muscle index (SMI) from the baseline to 12 weeks. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) and the Patient-Generated Subjective Global Assessment (PG-SGA) were used as paper questionnaires to assess the QoL and nutritional status of the patients. Intention-to-treat and per-protocol analyses were conducted. Regarding the study data collection time points, we assessed the nutritional status and QoL at the baseline (T0), and at 4 (T1), 8 (T2), and 12 (T3) weeks. Abdominal computed tomography (CT) imaging was conducted at the baseline and after 8 weeks for tumor response and SMI evaluation. The skeletal muscle area (cm2) was calculated using routine CT images. The cross-sectional areas (cm2) of the L3 skeletal muscles were analyzed.Between February 2017 and January 2018, 48 patients were assessed for eligibility. Totally 40 patients with pancreatic cancer were included by random allocation. Only 17 participants in the Noom user group and 16 in the non-Noom user group completed all follow-ups. All the study participants showed a significant improvement in the nutritional status according to the PG-SGA score regardless of Noom app usage. Noom users showed statistically significant improvements on the global health status (GHS) and QoL scales compared to non-Noom users, based on the EORTC QLQ (P=.004). The SMI decreased in both groups during chemotherapy (Noom users, 49.08±12.27 cm2/m2 to 46.08±10.55 cm2/m2; non-Noom users, 50.60±9.05 cm2/m2 to 42.97±8.12 cm2/m2). The decrement was higher in the non-Noom user group than in the Noom user group, but it was not statistically significant (-13.96% vs. -3.27%; P=.11).This pilot study demonstrates that a mobile app-based approach is beneficial for nutritional and psychological support for PDAC patients receiving chemotherapy.ClinicalTrials.gov NCT04109495; https://clinicaltrials.gov/ct2/show/NCT04109495." @default.
• W3176430891 created "2021-07-05" @default.
• W3176430891 creator A5002443895 @default.
• W3176430891 creator A5003266453 @default.
• W3176430891 creator A5035695627 @default.
• W3176430891 creator A5041839753 @default.
• W3176430891 creator A5046089418 @default.
• W3176430891 creator A5050431257 @default.
• W3176430891 creator A5070000246 @default.
• W3176430891 creator A5074361224 @default.
• W3176430891 creator A5084067051 @default.
• W3176430891 creator A5087762681 @default.
• W3176430891 creator A5089138431 @default.
• W3176430891 date "2021-08-31" @default.
• W3176430891 modified "2023-10-04" @default.
• W3176430891 title "Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial" @default.
• W3176430891 cites W1898606210 @default.
• W3176430891 cites W1932716280 @default.
• W3176430891 cites W1982946927 @default.
• W3176430891 cites W1988419318 @default.
• W3176430891 cites W1991877871 @default.
• W3176430891 cites W2006627740 @default.
• W3176430891 cites W2012059461 @default.
• W3176430891 cites W2015675622 @default.
• W3176430891 cites W2016318571 @default.
• W3176430891 cites W2036610278 @default.
• W3176430891 cites W2037658206 @default.
• W3176430891 cites W2062078253 @default.
• W3176430891 cites W2068101666 @default.
• W3176430891 cites W2074247824 @default.
• W3176430891 cites W2089979138 @default.
• W3176430891 cites W2107089530 @default.
• W3176430891 cites W2111855180 @default.
• W3176430891 cites W2118558111 @default.
• W3176430891 cites W2118598881 @default.
• W3176430891 cites W2130607817 @default.
• W3176430891 cites W2136238059 @default.
• W3176430891 cites W2145280166 @default.
• W3176430891 cites W2147016542 @default.
• W3176430891 cites W2181635775 @default.
• W3176430891 cites W2196089705 @default.
• W3176430891 cites W2256738791 @default.
• W3176430891 cites W2419063376 @default.
• W3176430891 cites W2552595635 @default.
• W3176430891 cites W2561425398 @default.
• W3176430891 cites W2593738187 @default.
• W3176430891 cites W2626721982 @default.
• W3176430891 cites W2781276926 @default.
• W3176430891 cites W2784374589 @default.
• W3176430891 cites W2787807749 @default.
• W3176430891 cites W2792278932 @default.
• W3176430891 cites W2793758417 @default.
• W3176430891 cites W2793956245 @default.
• W3176430891 cites W2799561878 @default.
• W3176430891 cites W2800575252 @default.
• W3176430891 cites W2880151681 @default.
• W3176430891 cites W2891505890 @default.
• W3176430891 cites W2899927465 @default.
• W3176430891 cites W2901121652 @default.
• W3176430891 cites W2908183275 @default.
• W3176430891 cites W2908411629 @default.
• W3176430891 cites W2912535286 @default.
• W3176430891 cites W2930802049 @default.
• W3176430891 cites W2955047361 @default.
• W3176430891 cites W2965603228 @default.
• W3176430891 cites W2971851579 @default.
• W3176430891 cites W2995196726 @default.
• W3176430891 cites W3010995825 @default.
• W3176430891 cites W3023645215 @default.
• W3176430891 cites W3037238948 @default.
• W3176430891 cites W4210976084 @default.
• W3176430891 doi "https://doi.org/10.2196/21088" @default.
• W3176430891 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8441607" @default.
• W3176430891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34463630" @default.
• W3176430891 hasPublicationYear "2021" @default.
• W3176430891 type Work @default.
• W3176430891 sameAs 3176430891 @default.
• W3176430891 citedByCount "12" @default.
• W3176430891 countsByYear W31764308912022 @default.
• W3176430891 countsByYear W31764308912023 @default.
• W3176430891 crossrefType "journal-article" @default.
• W3176430891 hasAuthorship W3176430891A5002443895 @default.
• W3176430891 hasAuthorship W3176430891A5003266453 @default.
• W3176430891 hasAuthorship W3176430891A5035695627 @default.
• W3176430891 hasAuthorship W3176430891A5041839753 @default.
• W3176430891 hasAuthorship W3176430891A5046089418 @default.
• W3176430891 hasAuthorship W3176430891A5050431257 @default.
• W3176430891 hasAuthorship W3176430891A5070000246 @default.
• W3176430891 hasAuthorship W3176430891A5074361224 @default.
• W3176430891 hasAuthorship W3176430891A5084067051 @default.
• W3176430891 hasAuthorship W3176430891A5087762681 @default.
• W3176430891 hasAuthorship W3176430891A5089138431 @default.
• W3176430891 hasBestOaLocation W31764308911 @default.
• W3176430891 hasConcept C121608353 @default.
• W3176430891 hasConcept C126322002 @default.
• W3176430891 hasConcept C159110408 @default.
• W3176430891 hasConcept C168563851 @default.
• W3176430891 hasConcept C1862650 @default.

• next